Sunshine Biopharma (SBFM) said Wednesday that it completed additional studies of its K1.1 mRNA lipid nanoparticle product, which confirmed it as a novel therapeutic agent for liver cancer.
Under repeated dosing, the mRNA product was found to reduce the growth of three different types of human hepatocellular carcinoma tumors in mice, with good tolerability, the company said.
The company said it is now conducting additional studies to define the optimum dosing of truncated version of the product, which is said to offer better efficacy at lower doses.
Sunshine Biopharma shares were 49% higher in recent premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.